עמוד 1 מ 17 תוצאות
BACKGROUND
1. Field of the Invention
The present invention relates to a metabolite of a xanthine Phosphodiesterase type 5 ("PDE 5") inhibitor useful for treatment of erectile dysfunction, and derivatives, formulations and processes related thereto.
2. Background
U.S. patent application Ser. No.
BACKGROUND OF THE INVENTION
Over half of all new cancers are skin cancers and its incidence is on the rise due to increased recreational exposure to sunlight and depletion of the ozone layer (American Cancer Society's 2004 Facts & Figures; Nataraj, et al. (1995) Photochem. Photobiol. 62:218-230;
TECHNICAL FIELD
The present invention relates to an agent containing a xanthine oxidase inhibitor as an active ingredient for overcoming anti-cancer agent resistance.
PRIOR ART
Chemotherapy is indispensable for cancer treatment. On the other hand, cancer often develops resistance to chemotherapy.
BACKGROUND OF THE INVENTION
This invention relates to the inhibition of activity of leukocyte derived cytokines, such as interleukin-1 and tumor necrosis factor, in humans and mammals. More specifically, this invention provides a method of inhibiting the activity of cytokines to arrest or alleviate
BACKGROUND OF THE INVENTION
This invention relates to the inhibition of activity of leukocyte derived cytokines, such as interleukin-1 and tumor necrosis factor, in humans and mammals. More specifically, this invention provides a method of inhibiting the activity of cytokines to arrest or alleviate
BACKGROUND OF THE INVENTION
The invention relates to the inhibition of activity of leukocyte derived cytokines, such as interleukin-1 and tumor necrosis factor, in humans and mammals. More specifically, this invention provides a method of inhibiting the activity of cytokines to arrest or alleviate
BACKGROUND OF THE INVENTION
This invention relates to the inhibition of activity of leukocyte derived cytokines, such as interleukin-1 and tumor necrosis factor, in humans and mammals. More specifically, this invention provides a method of inhibiting the activity of cytokines to arrest or alleviate
BACKGROUND OF THE INVENTION
This invention relates to the inhibition of activity of leukocyte derived cytokines, such as interleukin-1 and tumor necrosis factor, in humans and mammals. More specifically, this invention provides a method of inhibiting the activity of cytokines to arrest or alleviate
The present invention relates to the use of cocoa polyphenols for treating prostate hyperplasia, to a specific cocoa extract and to the uses of said extract in the pharmaceutical and food sectors.
The invention more specifically relates to the use of cocoa polyphenols for preventively or curatively
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2014/059912 filed Mar. 28, 2014, claiming priority based on Japanese Patent Application No. 2013-072788 filed Mar. 29, 2013, the contents of all of which are incorporated herein by
FIELD OF THE INVENTION
The invention pertains to methods of administering active agents to inhibit unwanted bone resorption, and pharmaceutical compositions and articles containing such active agents.
BACKGROUND OF THE INVENTION
The unwanted loosening of orthopaedic implants of all types, including
BACKGROUND OF THE INVENTION
It is known that the definition of the term tumor necrosis factor (TNF) includes two cytotoxic factors (TNF- .alpha. and TNF-.beta.) which are essentially formed by activated lymphocytes and monocytes. The term TNF derives from the property which initially attracted
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2014/052154 filed Jan. 30, 2014, claiming priority based on Japanese Patent Application No. 2013-017167 filed Jan. 31, 2013, the contents of all of which are incorporated herein by
This application is a U.S. national stage of International Application No. PCT/JP2004/003315 filed Mar. 12, 2004.
TECHNICAL FIELD
The present invention relates to a novel agent for suppressing tumorigenesis.
BACKGROUND ART
As a therapeutic drug for gout and hyperuricemia, allopurinol having a
BACKGROUND OF THE INVENTION
(a) Field of the Invention
The present invention relates to a group of antitumor agents which by themselves are not toxic and exhibit an improved tumor selective cytotoxic action due to their preferential accumulation in tumor tissue only after subsequent administration